Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 76
- Registration Number
- NCT01816971
- Locations
- 🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦Princess Margaret, Toronto, Ontario, Canada
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
- Conditions
- Interventions
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 7
- Registration Number
- NCT01813227
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT01812720
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01789242
- Locations
- 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT01775930
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
- Conditions
- Interventions
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Ajai Chari
- Target Recruit Count
- 13
- Registration Number
- NCT01775553
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
- Conditions
- Stage IA Mycosis Fungoides/Sezary SyndromeStage I Cutaneous T-cell Non-Hodgkin LymphomaStage IIB Mycosis Fungoides/Sezary SyndromeRecurrent Mycosis Fungoides/Sezary SyndromeStage IVB Mycosis Fungoides/Sezary SyndromeStage IIA Mycosis Fungoides/Sezary SyndromeStage IIIB Mycosis Fungoides/Sezary SyndromeStage IV Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaStage IB Mycosis Fungoides/Sezary Syndrome
- Interventions
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 7
- Registration Number
- NCT01738594
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT01729104
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 45
- Registration Number
- NCT01690143
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸UAB, Birmingham, Alabama, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 116
- Registration Number
- NCT01677858
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Fresno, California, United States
🇺🇸James R. Berenson M.D. Inc., West Hollywood, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.